Skip to main content

Table 1 Recipient/donor baseline and clinical characteristics of ABO-compatible and ABO-identical LTx

From: ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation

Variables ABO-compatible (n = 53) ABO-identical (n = 262) p-value
Recipient data    
Recipients major indication    0.240
 COPD 10 (18.9%) 64 (24.4%)  
 AAT1 9 (17.0%) 49 (18.7%)  
 PH 7 (13.2%) 29 (11.1%)  
 CF 15 (28.3%) 43 (16.4%)  
 PF 9 (17.0%) 35 (13.4%)  
 Others 2 (3.8%) 25 (9.5%)  
 Graft failure (Re-LTx) 1 (1.8%) 17 (6.5%)  
 CMV serology (pos) 39 (73.6%) 205 (78.2%) 0. 573
 EBV serology (pos) 37 (69.8%) 184 (70.2%) 0. 920
 Toxoplasma serology (pos) 14 (26.4%) 62 (23.7%) 0. 680
 CMV-mismatch 8 (15.1%) 41 (15.6%) 0. 911
 EBV-mismatch 5 (9.4%) 17 (6.5%) 0. 448
 Toxoplasma mismatch 6 (11.3%) 31 (11.8%) 0. 916
 Weight (kg) 64. 3 ± 19. 9 59. 8 ± 12. 5 0. 032
 Recipient/Donor weight ratio 0. 9 (0. 4–3. 1) 0. 8 (0. 4–1. 6) 0. 034
 Height (cm) 169. 1 ± 9. 1 168. 6 ± 10. 4 0. 703
 Recipient/Donor height ratio 1. 0 (0. 9–2. 4) 0. 9 (0. 8–1. 1) 0. 692
 BMI 22. 2 ± 4. 2 20. 9 ± 3. 7 0. 045
 Male 28 (52.8%) 124 (47.3%) 0. 465
 Gender mismatch 16 (30.2%) 90 (34.4%) 0. 523
 Age (years) 45. 5 (12. 2–70. 6) 52. 9 (12. 4–72. 0) 0. 159
 Recipient/Donor age ratio 0. 97 (0. 30–3. 92) 1. 03 (0. 27–3. 99) 0. 102
 Waiting list (days) 49.0 (2. 0–641. 0) 89. 0 (1. 0–1717. 0) 0. 048
Lab values    
 FVC (liters) 2. 0 (0. 7–5. 2) 2. 1 (0. 3–5. 3) 0. 233
 FEV1 (liters) 0. 9 (0. 2–2. 6) 0. 8 (0. 2–3. 4) 0. 735
 6MWT (%) 39. 4 ± 20. 3 38. 6 ± 19. 4 0. 813
 P-ALT (μkat/L) 0. 4 (0. 1–9. 7) 0. 4 (0. 1–1. 6) 0. 128
 P-AST (μkat/L) 0.5 (0. 2–10. 0) 0. 4 (0. 2–2. 3) 0. 340
 P-creatinine (μmol/L) 66 (22–234) 62 (26–217) 0. 255
 Pulm. pressure > 25mmhg 20 (37.8%) 70 (26.7%) 0. 110
Tx-type    0. 121
 SLTx 14 (26.5%) 86 (32.8%)  
 DLTx 36 (67.9%) 157 (59.9%)  
 HLTx 2 (3.8%) 2 (0.8%)  
 Re-LTx 1 (1.8%) 17 (6.5%)  
 SLTx 1 (100%) 9 (52.9%)  
 DLTx 0 (0%) 8 (47.1%)  
 ATG 35 (66.0%) 172 (65.6%) 0. 908
Pre-op Life support    
 Mechanical ventilation 2 (3.8%) 12 (4.6%) 0. 795
 ECMO 3 (5.7%) 9 (3.4%) 0. 673
Donor data    
 CMV serology (pos) 32 (60.4%) 172 (65.6%) 0. 547
 EBV serology (pos) 22 (41.5%) 139 (53.1%) 0. 119
 Toxoplasma serology (pos) 8 (15.1%) 48 (18.3%) 0. 568
 Weight (kg) 70 (19–180) 71 (40–105) 0. 901
 Height (cm) 170 (70–198) 170 (150–190) 0. 886
 BMI 23. 9 (6. 2–34. 6) 23. 9 (14. 7–35. 9) 0. 999
 Male 27 (50.9%) 119 (45.4%) 0. 506
 Age (years) 50. 5 (12. 2–71. 4) 47. 0 (7. 8–75. 4) 0. 463
  1. Data are mean (SD), number (%), or median (range). The numbers are based on patients with data available
  2. Entries are bold due to being under 0.05 which are significant results
  3. COPD chronic obstructive pulmonary disease, AAT1 Alpha 1-antitrypsin deficiency, PH pulmonary hypertension, CF cystic fibrosis; PF, pulmonary fibrosis, CMV cytomegalovirus; EBV Epstein-barr virus; BMI, body-mass index, FVC forced volume vital capacity, FEV1 forced volume expiratory capacity 1 s, 6MWT 6-min walking test, AST aspartate transaminase; ALT alanine transaminase, SLTx, single-lung transplantation, DLTx double-lung transplantation, HLTx heart-lung transplantation, Re-LTx re-lungtransplantation, ATG anti-thymocyte globulin, ECMO extracorporeal membrane oxygenation